Robert W Yeh

List of Publications by Year
in descending order

434 papers	34,129 citations	22099 59 h-index	4101 175 g-index
490 all docs	490 docs citations	490 times ranked	41660 citing authors

#	Article	IF	Citations
1	Heart Disease and Stroke Statisticsâ€"2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
2	Heart Disease and Stroke Statisticsâ€"2016 Update. Circulation, 2016, 133, e38-360.	1.6	5,447
3	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	1.0	3,048
4	Executive Summary: Heart Disease and Stroke Statisticsâ€"2016 Update. Circulation, 2016, 133, 447-454.	1.6	2,093
5	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166.	13.9	1,645
6	Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine, 2010, 362, 2155-2165.	13.9	1,444
7	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2016, 315, 1735.	3.8	759
8	Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. JAMA - Journal of the American Medical Association, 2020, 323, 2192.	3.8	577
9	Executive Summary: Heart Disease and Stroke Statisticsâ€"2015 Update. Circulation, 2015, 131, 434-441.	1.6	509
10	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
11	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
12	Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. JAMA - Journal of the American Medical Association, 2018, 320, 2542.	3.8	278
13	Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 2016, 9, 1-9.	1.1	276
14	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation, 2019, 140, 420-433.	1.6	263
15	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 65, 2211-2221.	1.2	240
16	Early Procedural and Health Status Outcomes After Chronic Total OcclusionÂAngioplasty. JACC: Cardiovascular Interventions, 2017, 10, 1523-1534.	1.1	234
17	A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction. Journal of the American Society of Nephrology: JASN, 2013, 24, 1330-1338.	3.0	233
18	Nonculprit Plaques in Patients With Acute Coronary Syndromes Have More Vulnerable Features Compared With Those With Nonâ€"Acute Coronary Syndromes. Circulation: Cardiovascular Imaging, 2012, 5, 433-440.	1.3	188

#	Article	IF	Citations
19	Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiology, 2019, 4, 332.	3.0	178
20	Community-Level Factors Associated With Racial And Ethnic Disparities In COVID-19 Rates In Massachusetts. Health Affairs, 2020, 39, 1984-1992.	2.5	175
21	The Hybrid Approach to ChronicÂTotalÂOcclusion PercutaneousÂCoronaryÂIntervention. JACC: Cardiovascular Interventions, 2018, 11, 1325-1335.	1.1	159
22	Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart, 2015, 101, 1631-1638.	1.2	158
23	Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet, The, 2015, 385, 792-798.	6.3	151
24	Readmission Rates After Passage of the Hospital Readmissions Reduction Program. Annals of Internal Medicine, 2017, 166, 324.	2.0	147
25	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147
26	Cardiovascular Deaths During the COVID-19ÂPandemic in the United States. Journal of the American College of Cardiology, 2021, 77, 159-169.	1.2	147
27	Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. International Journal of Cardiology, 2015, 198, 222-228.	0.8	137
28	Cardiovascular Care Facts. Journal of the American College of Cardiology, 2013, 62, 1931-1947.	1.2	135
29	Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiology, 2019, 4, 1084.	3.0	124
30	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1719-1726.	1.3	117
31	Sex Differences in Faculty Rank Among Academic Cardiologists in the United States. Circulation, 2017, 135, 506-517.	1.6	115
32	Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). Journal of the American Heart Association, 2015, 4, .	1.6	111
33	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	1.2	111
34	A Plasma Longâ€Chain Acylcarnitine Predicts Cardiovascular Mortality in Incident Dialysis Patients. Journal of the American Heart Association, 2013, 2, e000542.	1.6	109
35	Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2014, 130, 2295-2301.	1.6	109
36	Comparison of Nonculprit Coronary Plaque Characteristics Between Patients With and Without Diabetes. JACC: Cardiovascular Interventions, 2012, 5, 1150-1158.	1.1	106

#	Article	IF	Citations
37	Trends and Outcomes of Restenosis AfterÂCoronary Stent Implantation inÂtheÂUnited States. Journal of the American College of Cardiology, 2020, 76, 1521-1531.	1.2	106
38	Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ: British Medical Journal, 2018, 363, k5094.	2.4	103
39	Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiology, 2019, 4, 671.	3.0	102
40	Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 70, 2213-2223.	1.2	99
41	Association Between Public Reporting of Outcomes With Procedural Management and Mortality for Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 65, 1119-1126.	1.2	98
42	Risk Adjustment of Ischemic Stroke Outcomes for Comparing Hospital Performance. Stroke, 2014, 45, 918-944.	1.0	94
43	Clinical Utility of the Japanâ€“Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions. Circulation: Cardiovascular Interventions, 2015, 8, e002171.	1.4	93
44	Comparison of Incidence and Time Course of Neoatherosclerosis Between Bare Metal Stents and Drug-Eluting Stents Using Optical Coherence Tomography. American Journal of Cardiology, 2012, 110, 933-939.	0.7	91
45	Comparison of Sixty-Fourâ€“Slice Multidetector Computed Tomographic Coronary Angiography to Coronary Angiography With Intravascular Ultrasound for the Detection of Transplant Vasculopathy. American Journal of Cardiology, 2006, 98, 877-884.	0.7	88
46	Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents. JAMA - Journal of the American Medical Association, 2015, 313, 1113.	3.8	82
47	Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. European Heart Journal, 2019, 40, 2231-2239.	1.0	81
48	The Hospital Readmissions Reduction Program â€" Time for a Reboot. New England Journal of Medicine, 2019, 380, 2289-2291.	13.9	79
49	DAPT Score Utility for Risk Prediction inÂPatients With or Without PreviousÂMyocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 2492-2502.	1.2	78
50	Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. Journal of the American College of Cardiology, 2013, 61, 2130-2138.	1.2	77
51	Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery. Annals of Thoracic Surgery, 2007, 83, 592-597.	0.7	76
52	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2020, 13, 1277-1287.	1.1	73
53	Fatal Hyperphosphatemia From a Phosphosoda Bowel Preparation. Journal of Clinical Gastroenterology, 2002, 34, 457-458.	1.1	72
54	Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. Circulation, 2021, 143, 2346-2354.	1.6	70

#	Article	IF	Citations
55	Argatroban: Update. American Heart Journal, 2006, 151, 1131-1138.	1.2	69
56	Adherence to Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review. Clinical Cardiology, 2014, 37, 505-513.	0.7	67
57	Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 120, 1285-1292.	0.7	66
58	Trends, Causes, and Outcomes of Hospitalizations for Homeless Individuals. Medical Care, 2019, 57, 21-27.	1.1	66
59	National trends, predictors of use, and in-hospital outcomes in mechanical circulatory support for cardiogenic shock. EuroIntervention, 2018, 13, 2152-2159.	1.4	66
60	<scp>SCAI</scp> position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheterization and Cardiovascular Interventions, 2020, 96, 346-362.	0.7	65
61	Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation, 2021, 143, 2229-2240.	1.6	64
62	Trends in Isolated Surgical Aortic ValveÂReplacement According to Hospital-BasedÂTranscatheter AorticÂValveÂReplacement Volumes. JACC: Cardiovascular Interventions, 2018, 11, 2148-2156.	1.1	63
63	Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention. Circulation, 2011, 124, 1557-1564.	1.6	60
64	Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. Journal of the American College of Cardiology, 2019, 73, 2636-2638.	1.2	59
65	A Prediction Model to Identify Patients at High Risk for 30-Day Readmission After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 429-435.	0.9	58
66	Surgical Candidacy and Selection Biases in Nonemergent Left Main Stenting. JACC: Cardiovascular Interventions, 2011, 4, 1020-1027.	1.1	57
67	Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device. JAMA Internal Medicine, 2015, 175, 1104.	2.6	57
68	Model Feedback in Bayesian Propensity Score Estimation. Biometrics, 2013, 69, 263-273.	0.8	56
69	Disparities in Care and Mortality Among Homeless Adults Hospitalized for Cardiovascular Conditions. JAMA Internal Medicine, 2020, 180, 357.	2.6	54
70	Variation in the Adoption of TransradialÂAccess for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 2242-2254.	1.1	53
71	Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 686-693.	0.7	52
72	Stent Thrombosis in Drug-Eluting or Bare-MetalÂStents in Patients Receiving DualÂAntiplateletÂTherapy. JACC: Cardiovascular Interventions, 2015, 8, 1552-1562.	1.1	51

#	Article	IF	Citations
73	Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. International Journal of Cardiology, 2016, 214, 428-437.	0.8	51
74	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thrombosis and Haemostasis, 2017, 117, 246-251.	1.8	51
75	Public Reporting in Cardiovascular Medicine. Circulation, 2015, 131, 1518-1527.	1.6	50
76	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation, 2017, 136, 2210-2219.	1.6	50
77	Benefits and Risks of Extended DualÂAntiplatelet Therapy After Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 138-147.	1.1	49
78	Causes of Short-Term Readmission After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 97-103.	1.4	48
79	Readmissions After Revascularization Procedures for Peripheral Arterial Disease. Annals of Internal Medicine, 2018, 168, 93.	2.0	48
80	Primary Results of the EVOLVE Short DAPT Study. Circulation: Cardiovascular Interventions, 2021, 14, e010144.	1.4	48
81	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation, 2016, 133, 1772-1782.	1.6	47
82	Clinical Interventions to Reduce Preventable Hospital Readmission After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 600-604.	0.9	47
83	Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach. JACC: Cardiovascular Interventions, 2019, 12, 346-358.	1.1	47
84	Disparities in Cardiovascular Mortality Between Black and White Adults in the United States, 1999 to 2019. Circulation, 2022, 146, 211-228.	1.6	47
85	Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk Patients. Stroke, 2012, 43, 3218-3224.	1.0	46
86	Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs. JAMA - Journal of the American Medical Association, 2021, 325, 1219.	3.8	46
87	New-Generation Coronary Stents: Current Data and Future Directions. Current Atherosclerosis Reports, 2017, 19, 14.	2.0	45
88	Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States. JAMA Cardiology, 2019, 4, 100.	3.0	45
89	Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. Health Affairs, 2019, 38, 585-593.	2.5	44
90	Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries. American Journal of Cardiology, 2019, 123, 132-138.	0.7	44

#	Article	IF	Citations
91	Proximal Versus Distal Embolic Protection for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2015, 8, 609-615.	1.1	43
92	Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. International Journal of Cardiology, 2016, 224, 50-56.	0.8	43
93	Treatment and Outcomes of Acute Myocardial Infarction Complicated by Shock After Public Reporting Policy Changes in New York. JAMA Cardiology, 2016, 1, 648.	3.0	43
94	Sources of Hospital Variation in Short-Term Readmission Rates After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 227-236.	1.4	42
95	Population Trends in Rates of Coronary Revascularization. JAMA Internal Medicine, 2015, 175, 454.	2.6	42
96	Mortality and Hospitalizations for Dually Enrolled and Nondually Enrolled Medicare Beneficiaries Aged 65 Years or Older, 2004 to 2017. JAMA - Journal of the American Medical Association, 2020, 323, 961.	3.8	42
97	Association Between Operator Procedure Volume and Patient Outcomes in Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 560-566.	0.9	41
98	Real-time fusion of coronary CT angiography with x-ray fluoroscopy during chronic total occlusion PCI. European Radiology, 2017, 27, 2464-2473.	2.3	41
99	Features of Coronary Plaque in Patients With Metabolic Syndrome and Diabetes Mellitus Assessed by 3-Vessel Optical Coherence Tomography. Circulation: Cardiovascular Imaging, 2013, 6, 665-673.	1.3	40
100	Riskâ€Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention. Journal of the American Heart Association, 2013, 2, e000174.	1.6	40
101	Population Trends From 2000-2011 in Nuclear Myocardial Perfusion Imaging Use. JAMA - Journal of the American Medical Association, 2014, 311, 1248.	3.8	40
102	Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction. JAMA Cardiology, 2019, 4, 120.	3.0	40
103	Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: Single Center Clinical Presentation. Journal of the American Heart Association, 2020, 9, e014738.	1.6	39
104	Causes of late mortality with dual antiplatelet therapy after coronary stents. European Heart Journal, 2015, 37, ehv614.	1.0	38
105	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease. JACC: Cardiovascular Interventions, 2017, 10, 942-954.	1.1	38
106	Short-term rehospitalization across the spectrum of age and insurance types in the United States. PLoS ONE, 2017, 12, e0180767.	1.1	38
107	Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries. JAMA Internal Medicine, 2021, 181, 1071.	2.6	38
108	Geographic Disparities in the Incidence and Outcomes of Hospitalized Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 197-204.	0.9	37

#	Article	IF	Citations
109	Reporting Trends and Outcomes in ST-Segmentâ€“Elevation Myocardial Infarction National Hospital Quality Assessment Programs. Circulation, 2014, 129, 194-202.	1.6	37
110	Prevalence, indications and management of balloon uncrossable chronic total occlusions: Insights from a contemporary multicenter US registry. Catheterization and Cardiovascular Interventions, 2017, 90, 12-20.	0.7	37
111	Pre-procedural Risk Quantification for Carotid Stenting Using the CAS Score. Journal of the American College of Cardiology, 2012, 60, 1617-1622.	1.2	36
112	Comparison of Short- and Long-Term Cardiac Mortality inÂEarly Versus Late Stent Thrombosis (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	36
113	Comparison of Reperfusion Strategies for STâ€Segmentâ€“Elevation Myocardial Infarction: A Multivariate Network Metaâ€analysis. Journal of the American Heart Association, 2020, 9, e015186.	1.6	36
114	Clinical Preventability of 30â€Day Readmission After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2014, 3, e001290.	1.6	34
115	Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. American Heart Journal, 2015, 169, 222-233.e5.	1.2	34
116	Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock: Impact of Age on In-Hospital Mortality, Length of Stay, and Costs. Critical Care Medicine, 2019, 47, e214-e221.	0.4	34
117	Impact of Calcium on Chronic Total Occlusion Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 120, 40-46.	0.7	33
118	A Survey of Interventional Cardiologistsâ€™ Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. JAMA Cardiology, 2018, 3, 629.	3.0	33
119	Rethinking the Epidemiology of Acute Myocardial Infarction. Archives of Internal Medicine, 2010, 170, 759.	4.3	32
120	Usefulness of the Seattle Heart Failure Model to Identify Adults With Congenital Heart Disease at High Risk of Poor Outcome. American Journal of Cardiology, 2014, 113, 865-870.	0.7	32
121	Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005048.	0.9	32
122	High Burden of 30â€Day Readmissions After Acute Venous Thromboembolism in the United States. Journal of the American Heart Association, 2018, 7, .	1.6	32
123	Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism. Chest, 2020, 157, 645-653.	0.4	32
124	Analysis of Cardiac Dimensions, Mass and Function in Heart Transplant Recipients Using 64-slice Multi-detector Computed Tomography. Journal of Heart and Lung Transplantation, 2007, 26, 478-484.	0.3	31
125	Predicting the Presence of an Acute Coronary Lesion Among Patients Resuscitated From Cardiac Arrest. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	31
126	Intensive care use and mortality among patients with ST elevation myocardial infarction: retrospective cohort study. BMJ: British Medical Journal, 2019, 365, l1927.	2.4	31

#	Article	IF	Citations
127	Comparison of Transradial Versus Transfemoral Percutaneous Coronary Intervention in Routine Practice. Journal of the American College of Cardiology, 2013, 62, 2147-2148.	1.2	30
128	Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. American Journal of Cardiology, 2017, 120, 1070-1076.	0.7	30
129	Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. Journal of the American Heart Association, 2016, 5, .	1.6	29
130	Use and Effectiveness of Bivalirudin VersusÂUnfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2016, 9, 2376-2386.	1.1	29
131	Academic Cardiology and Social Media. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004736.	0.9	29
132	Hospital Variation in the Utilization of Short-Term Nondurable Mechanical Circulatory Support in Myocardial Infarction Complicated by Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2019, 12, e007270.	1.4	29
133	Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003464.	1.4	28
134	The Rise and Fall of Mandatory Cardiac Bundled Payments. JAMA - Journal of the American Medical Association, 2018, 319, 335.	3.8	28
135	Usefulness of Atherectomy in Chronic Total Occlusion Interventions (from the PROGRESS-CTO) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	28
136	Association of Homelessness with Hospital Readmissionsâ€"an Analysis of Three Large States. Journal of General Internal Medicine, 2020, 35, 2576-2583.	1.3	28
137	Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005977.	0.9	28
138	Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. Annals of Internal Medicine, 2022, 175, 765-773.	2.0	27
139	Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A metaâ€analysis and critical examination of current methodologies. Catheterization and Cardiovascular Interventions, 2014, 83, 975-983.	0.7	26
140	Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2014, 7, 171-177.	1.1	26
141	Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 477-485.	0.9	26
142	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. JAMA Cardiology, 2019, 4, 110.	3.0	26
143	Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. JAMA - Journal of the American Medical Association, 2020, 323, 1614.	3.8	26
144	Do Postmarketing Surveillance Studies Represent Real-World Populations?. Circulation, 2011, 123, 1384-1390.	1.6	25

#	Article	IF	Citations
145	Clinical Referral Patterns for Carotid Artery Stenting Versus Carotid Endarterectomy. Circulation: Cardiovascular Interventions, 2011, 4, 88-94.	1.4	25
146	Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). American Journal of Cardiology, 2016, 117, 1267-1271.	0.7	25
147	5-Year Safety and Efficacy of ResoluteÂŽotarolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2017, 10, 247-254.	1.1	25
148	2016 <scp>R</scp>evision of the SCAI position statement on public reporting. Catheterization and Cardiovascular Interventions, 2017, 89, 269-279.	0.7	25
149	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005795.	1.4	25
150	Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2008, 25, 214-218.	1.0	24
151	Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. Catheterization and Cardiovascular Interventions, 2017, 89, E90-E98.	0.7	24
152	Decision Tools to Improve Personalized Care in Cardiovascular Disease. Circulation, 2017, 135, 1097-1100.	1.6	24
153	Public Reporting of Percutaneous Coronary Intervention Outcomes. JAMA Cardiology, 2018, 3, 635.	3.0	24
154	Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. JAMA - Journal of the American Medical Association, 2021, 325, 445.	3.8	24
155	Procedural variation in the performance of primary percutaneous coronary intervention for STâ€elevation myocardial infarction: A SCAIâ€based survey study of US interventional cardiologists. Catheterization and Cardiovascular Interventions, 2014, 83, 721-726.	0.7	23
156	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. American Heart Journal, 2019, 212, 64-71.	1.2	23
157	In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions, 2019, 12, e007338.	1.4	23
158	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 203-213.	1.6	23
159	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 774418.	1.1	23
160	Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?. American Heart Journal, 2014, 168, 103-109.	1.2	22
161	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. JAMA Cardiology, 2017, 2, 478.	3.0	22
162	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. American Heart Journal, 2018, 205, 110-117.	1.2	22

#	Article	IF	Citations
163	Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2019, 12, e007877.	1.4	22
164	Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 616-624.e3.	0.4	22
165	Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC: Cardiovascular Interventions, 2021, 14, 278-288.	1.1	22
166	Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes. American Journal of Cardiology, 2007, 100, 1734-1738.	0.7	21
167	Takotsubo Cardiomyopathy Complicated by Cardiac Tamponade. Circulation, 2010, 122, 1239-1241.	1.6	21
168	Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 2077-2085.	1.1	21
169	Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	1.6	21
170	The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opinion on Drug Safety, 2017, 16, 561-572.	1.0	21
171	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	2.6	21
172	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention viaÂSaphenous Vein Graft. JACC: Cardiovascular Interventions, 2020, 13, 517-526.	1.1	21
173	Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 96-102.	0.9	20
174	The Data Extraction and Longitudinal Trend Analysis Network Study of Distributed Automated Postmarket Cardiovascular Device Safety Surveillance. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 38-46.	0.9	20
175	National Trends in Hospitalizations of Adults With Tetralogy of Fallot. American Journal of Cardiology, 2016, 118, 906-911.	0.7	20
176	Health Insurance and Mobile Health Devices. JAMA - Journal of the American Medical Association, 2019, 321, 1767.	3.8	20
177	Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation. American Journal of Cardiology, 2020, 125, 1317-1323.	0.7	20
178	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006589.	0.9	20
179	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation, 2022, 145, 97-106.	1.6	20
180	Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting. Circulation: Cardiovascular Interventions, 2013, 6, 131-138.	1.4	19

#	Article	IF	Citations
181	Hospital Variation in Carotid StentingÂOutcomes. JACC: Cardiovascular Interventions, 2015, 8, 858-863.	1.1	19
182	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation, 2016, 134, 989-998.	1.6	19
183	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiology, 2016, 1, 655.	3.0	19
184	Predictors of Excess Patient Radiation Exposure During Chronic Total Occlusion Coronary Intervention: Insights From a Contemporary Multicentre Registry. Canadian Journal of Cardiology, 2017, 33, 478-484.	0.8	19
185	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 651-658.	1.1	19
186	Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1777-1785.	1.1	19
187	Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPENâ€CTO registry. Catheterization and Cardiovascular Interventions, 2021, 97, 1162-1173.	0.7	19
188	Dissemination of Transcatheter Aortic Valve Replacement in the United States. Journal of the American College of Cardiology, 2021, 78, 794-806.	1.2	19
189	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral ArteryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	1.2	19
190	Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2015, 372, 1371-1374.	13.9	18
191	Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Medicine, 2011, 9, 78.	2.3	17
192	Percutaneous Coronary Interventions without On-Site Cardiac Surgical Backup. New England Journal of Medicine, 2012, 366, 1814-1823.	13.9	17
193	Transradial Versus Transfemoral Access inÂPatients Undergoing Rescue Percutaneous Coronary Intervention AfterÂFibrinolytic Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1868-1876.	1.1	17
194	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation, 2017, 135, 1720-1732.	1.6	17
195	Time-Course of Cause-Specific Hospital Admissions During Snowstorms: An Analysis of Electronic Medical Records From Major Hospitals in Boston, Massachusetts. American Journal of Epidemiology, 2017, 185, 283-294.	1.6	17
196	Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. Journal of the American Heart Association, 2018, 7, .	1.6	17
197	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e008231.	1.4	17
198	Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Internal Medicine, 2019, 179, 259.	2.6	17

#	Article	IF	Citations
199	Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. Vascular Medicine, 2021, 26, 317-325.	0.8	17
200	Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries. Journal of Invasive Cardiology, 2016, 28, 44-51.	0.4	17
201	Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology, 2010, 35, 123-170.	1.1	16
202	Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program. Annals of Internal Medicine, 2021, 174, 86-92.	2.0	16
203	Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	15
204	Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004397.	0.9	15
205	Etiologies, trends, and predictors of readmission in STâ€elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 94, 905-914.	0.7	15
206	Public Reporting of Percutaneous Coronary Intervention Outcomes. Journal of the American College of Cardiology, 2019, 73, 2604-2608.	1.2	15
207	Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2019, 4, 16.	3.0	15
208	Readmissions after acute type B aortic dissection. Journal of Vascular Surgery, 2020, 72, 73-83.e2.	0.6	15
209	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. JAMA Cardiology, 2020, 5, 515.	3.0	15
210	Frailty in patients undergoing percutaneous left atrial appendage closure. Heart Rhythm, 2022, 19, 814-821.	0.3	15
211	Management Strategy in 249 Consecutive Patients With Obstructive Hypertrophic Cardiomyopathy Referred to a Dedicated Program. American Journal of Cardiology, 2012, 110, 1169-1174.	0.7	14
212	Unprotected carotid artery stenting in modern practice. Catheterization and Cardiovascular Interventions, 2014, 83, 595-602.	0.7	14
213	Instrumental Variable Analysis to Compare Effectiveness of Stents in the Extremely Elderly. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 118-124.	0.9	14
214	Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. American Heart Journal, 2016, 178, 190-197.	1.2	14
215	Prevalence and Outcomes of Percutaneous Coronary Interventions for Ostial Chronic Total Occlusions: Insights From a Multicenter Chronic Total Occlusion Registry. Canadian Journal of Cardiology, 2018, 34, 1264-1274.	0.8	14
216	Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segmentâ€“Elevation Myocardial Infarction in the United States. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006275.	0.9	14

#	Article	IF	Citations
217	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. Journal of the American College of Cardiology, 2021, 77, 1977-1990.	1.2	14
218	Contrast Utilization During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. Journal of Invasive Cardiology, 2016, 28, 288-94.	0.4	14
219	Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, .	0.9	14
220	Management of Patients With Cardiac Arrest Complicating Myocardial Infarction in New York Before and After Public Reporting Policy Changes. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	13
221	Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. Journal of the American Heart Association, 2021, 10, e021117.	1.6	13
222	Patient-Reported Outcomes in Cardiology. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004794.	0.9	13
223	National Trends in Hospitalizations for Patients With Single-Ventricle Anatomy. American Journal of Cardiology, 2015, 116, 773-778.	0.7	12
224	Outcomes in Patients Undergoing PrimaryÂPercutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin VersusÂHeparin. JACC: Cardiovascular Interventions, 2017, 10, 1102-1111.	1.1	12
225	Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention. Circulation, 2017, 135, 1897-1907.	1.6	12
226	30-Day Episode Payments and HeartÂFailure Outcomes Among MedicareÂBeneficiaries. JACC: Heart Failure, 2018, 6, 379-387.	1.9	12
227	Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004â€“17. Health Affairs, 2021, 40, 289-296.	2.5	12
228	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008477.	1.6	12
229	Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheterization and Cardiovascular Interventions, 2008, 72, 116-120.	0.7	11
230	Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. Journal of the American Heart Association, 2014, 3, e000728.	1.6	11
231	Future of the PCI Readmission Metric. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 186-189.	0.9	11
232	Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. American Journal of Cardiology, 2018, 121, 1365-1372.	0.7	11
233	Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. American Heart Journal, 2018, 195, 151-152.	1.2	11
234	Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. American Journal of Cardiology, 2018, 122, 1843-1852.	0.7	11

#	Article	IF	Citations
235	Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. Circulation, 2019, 140, 969-971.	1.6	11
236	Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary intervention. Heart, 2020, 106, 441-446.	1.2	11
237	Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease. JAMA Network Open, 2021, 4, e2112800.	2.8	11
238	Days out of Institution after Tracheostomy and Gastrostomy Placement in Critically Ill Older Adults. Annals of the American Thoracic Society, 2022, 19, 424-432.	1.5	11
239	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S.ÂPractice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	1.1	11
240	Retrograde CTO-PCI of Native Coronary Arteries Via Left Internal Mammary Artery Grafts: Insights From a Multicenter U.S. Registry. Journal of Invasive Cardiology, 2018, 30, 89-96.	0.4	11
241	Mechanical Circulatory Support in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter U.S. Registry. Journal of Invasive Cardiology, 2018, 30, 81-87.	0.4	11
242	Dual Antiplatelet Therapy Duration Following Coronary Stenting â^—. Journal of the American College of Cardiology, 2015, 65, 787-790.	1.2	10
243	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal of the American Heart Association, 2020, 9, e013606.	1.6	10
244	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. JAMA Cardiology, 2020, 5, 765.	3.0	10
245	Population Trends in Rates of Percutaneous Coronary Interventions, 2010 to 2017. JAMA Cardiology, 2021, 6, 1219.	3.0	10
246	Approaches to percutaneous coronary intervention of right coronary artery chronic total occlusions: insights from a multicentre US registry. EuroIntervention, 2016, 12, e1326-e1335.	1.4	10
247	The Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease (OPTIMUM) Registry: Rationale and Design. Cardiovascular Revascularization Medicine, 2022, 41, 83-91.	0.3	10
248	Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions. Journal of Invasive Cardiology, 2018, 30, 43-50.	0.4	10
249	Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period. Journal of Thrombosis and Thrombolysis, 2010, 30, 276-280.	1.0	9
250	Association Between Leukocyte Telomere Length and Drug-Eluting Stent Strut Coverage by Optical Coherence Tomography. Journal of the American College of Cardiology, 2012, 59, 2218-2219.	1.2	9
251	Blood Transfusion in Myocardial Infarction. Journal of the American College of Cardiology, 2014, 64, 820-822.	1.2	9
252	Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circulation: Cardiovascular Interventions, 2018, 11, e005308.	1.4	9

#	Article	IF	Citations
253	Applicability of Publicly Reported Hospital Readmission Measures to Unreported Conditions and Other Patient Populations. Annals of Internal Medicine, 2018, 168, 631-639.	2.0	9
254	Trends in isolated aortic valve replacement in the United States in the early phase of expansion of TAVR. International Journal of Cardiology, 2019, 292, 68-72.	0.8	9
255	Intermediate procedural and health status outcomes and the clinical care pathways after chronic total occlusion angioplasty: A report from the <scp>OPENâ€CTO</scp> (outcomes, patient health) Tj ETQq1 1 0.784314 rgBT /Overlock Cardiovascular Interventions, 2021, 98, 626-635.	0.7	9
256	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. Circulation: Cardiovascular Interventions, 2020, 13, e009179.	1.4	9
257	Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States. JAMA Cardiology, 2021, 6, 574.	3.0	9
258	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. Journal of Thrombosis and Thrombolysis, 2021, 51, 675-681.	1.0	9
259	Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e3.	0.6	9
260	High-Risk Percutaneous Coronary Intervention in the Era of Public Reporting. Circulation, 2014, 129, 258-265.	1.6	8
261	Incidence and predictors of incomplete revascularization in a contemporary cohort. Coronary Artery Disease, 2016, 27, 191-198.	0.3	8
262	Contemporary Drug-Eluting Stent Platforms. Cardiology Clinics, 2017, 35, 281-296.	0.9	8
263	High-Risk Percutaneous Coronary Intervention in Public Reporting States: the Evidence, Exclusion of Critically Ill Patients, and Implications. Current Heart Failure Reports, 2017, 14, 514-518.	1.3	8
264	Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. American Heart Journal, 2019, 216, 53-61.	1.2	8
265	Relative Effects of the Hospital Readmissions Reduction Program on Hospitals That Serve Poorer Patients. Medical Care, 2019, 57, 968-976.	1.1	8
266	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.	1.6	8
267	Use of etomidate in patients with heart failure undergoing noncardiac surgery. British Journal of Anaesthesia, 2020, 125, 943-952.	1.5	8
268	Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate. American Heart Journal, 2020, 228, 44-46.	1.2	8
269	Equipment utilization in chronic total occlusion percutaneous coronary interventions: Insights from the PROGRESSâ€CTO registry. Catheterization and Cardiovascular Interventions, 2021, 97, 658-667.	0.7	8
270	Mortality, Length of Stay, and Cost of Weekend Admissions. Journal of Hospital Medicine, 2018, 13, 476-481.	0.7	8

#	Article	IF	Citations
271	Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1223-1235.	1.2	8
272	Association of Frailty With Treatment Selection and Longâ€Term Outcomes Among Patients With Chronic Limbâ€Threatening Ischemia. Journal of the American Heart Association, 2021, 10, e023138.	1.6	8
273	Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization. American Journal of Cardiology, 2006, 98, 419-421.	0.7	7
274	What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?. Blood Coagulation and Fibrinolysis, 2008, 19, 401-404.	0.5	7
275	Successful treatment of flecainide overdose with sustained mechanical circulatory support. HeartRhythm Case Reports, 2015, 1, 137-140.	0.2	7
276	Feasibility of a Tablet Computer System to Collect Patient-reported Symptom Severity in Patients Undergoing Diagnostic Coronary Angiography. Critical Pathways in Cardiology, 2015, 14, 139-145.	0.2	7
277	Contemporary Drug-Eluting Stent Platforms. Interventional Cardiology Clinics, 2016, 5, 331-347.	0.2	7
278	Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. Journal of the American College of Cardiology, 2017, 70, 1196-1197.	1.2	7
279	Incentivizing Transradial Access for Primary Percutaneous Coronary Intervention While Maintaining Timely Reperfusion. JAMA Cardiology, 2017, 2, 1057.	3.0	7
280	Inferior Vena Cava Filters and Mortality. JAMA Network Open, 2018, 1, e180453.	2.8	7
281	Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Interventions, 2019, 12, e007564.	1.4	7
282	Trends and predictors of early ablation for Atrial Fibrillation in a Nationwide population under age 65: a retrospective observational study. BMC Cardiovascular Disorders, 2020, 20, 161.	0.7	7
283	Rationale and Design of the SAFE-PAD Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007040.	0.9	7
284	Identification of Frailty Using a Claimsâ€Based Frailty Index in the CoreValve Studies: Findings from the EXTENDâ€FRAILTY Study. Journal of the American Heart Association, 2021, 10, e022150.	1.6	7
285	Rationale and design of a randomized study comparing the agent drug coated balloon to plain old balloon angioplasty in patients with In-stent restenosis. American Heart Journal, 2021, 241, 101-107.	1.2	7
286	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121007979.	0.9	7
287	Frequency and Outcomes of Ad Hoc Versus Planned Chronic Total Occlusion Percutaneous Coronary Intervention: Multicenter Experience. Journal of Invasive Cardiology, 2019, 31, 133-139.	0.4	7
288	Calcium-Triggered Short-Coupled Polymorphous Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 117-122.	0.5	6

#	Article	IF	Citations
289	Culprit only, multivessel, or staged multivessel intervention in STEMI: New insights or insurmountable methodologic obstacles?. Catheterization and Cardiovascular Interventions, 2014, 84, 923-924.	0.7	6
290	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. JAMA Cardiology, 2017, 2, 673.	3.0	6
291	Coronary artery spatial distribution of chronic total occlusions: Insights from a large US registry. Catheterization and Cardiovascular Interventions, 2017, 90, 23-30.	0.7	6
292	Personal and Professional Characteristics of U.S. Dual-Boarded Critical Care Cardiologists in 2015. Critical Care Medicine, 2017, 45, e1292-e1296.	0.4	6
293	Practical Improvements for Medical Device Evaluation. JAMA - Journal of the American Medical Association, 2017, 318, 332.	3.8	6
294	Public Reporting of Percutaneous Coronary Intervention Mortality in New York State. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	6
295	Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. Health Services Research, 2018, 53, 2185-2202.	1.0	6
296	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). Angiology, 2020, 71, 274-280.	0.8	6
297	Mitral Valve Surgical Volume and Transcatheter Mitral Valve Repair Outcomes: Impact of a Proposed Volume Requirement on Geographic Access. Journal of the American Heart Association, 2020, 9, e016140.	1.6	6
298	Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 273-279.	1.8	6
299	Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 569-578.	0.7	6
300	In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. Journal of Invasive Cardiology, 2018, 30, E113-E121.	0.4	6
301	Anticoagulant Agents in Acute Coronary Syndromes. Current Problems in Cardiology, 2011, 36, 127-168.	1.1	5
302	Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. Canadian Journal of Cardiology, 2016, 32, 1433-1439.	0.8	5
303	Utilization and outcomes of transcatheter aortic valve replacement in the United States shortly after device approval. Catheterization and Cardiovascular Interventions, 2017, 90, 830-838.	0.7	5
304	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheterization and Cardiovascular Interventions, 2018, 92, E348-E355.	0.7	5
305	Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS ONE, 2018, 13, e0205457.	1.1	5
306	The DAPT Score inÂSweden. Journal of the American College of Cardiology, 2019, 73, 113-114.	1.2	5

#	Article	IF	Citations
307	Medicaid Expansion and Ventricular Assist Device Implantation. Journal of the American College of Cardiology, 2020, 76, 1501-1502.	1.2	5
308	The DAPT Score Uncouples Bleeding and Ischemic Riskâ€¦Again. JACC: Cardiovascular Interventions, 2020, 13, 647-650.	1.1	5
309	New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	5
310	Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiology, 2022, 7, 110.	3.0	5
311	Development and validation of an echocardiographic algorithm to predict long-term mitral and tricuspid regurgitation progression. European Heart Journal Cardiovascular Imaging, 2022, 23, 1606-1616.	0.5	5
312	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007903.	0.9	5
313	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPENâ€CTO Registry. Journal of the American Heart Association, 2022, 11, e024056.	1.6	5
314	Update From the Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS122012074.	1.4	5
315	Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2009, 74, 359-364.	0.7	4
316	Choosing Methods to Minimize Confounding in Observational Studies. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 581-583.	0.9	4
317	Clinical factors and echocardiographic techniques related to the presence, size, and location of acoustic windows for leadless cardiac pacing. Europace, 2011, 13, 1760-1765.	0.7	4
318	Comparative effectiveness research: does one size fit all?. Statistics in Medicine, 2012, 31, 3062-3065.	0.8	4
319	Public reporting and coronary revascularization. Coronary Artery Disease, 2014, 25, 619-626.	0.3	4
320	Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	4
321	Differences Among Cardiologists in Rates of Positive Coronary Angiograms. Journal of the American Heart Association, 2015, 4, e002393.	1.6	4
322	Is multivessel intervention in STâ€elevation myocardial infarction associated with early harm? Insights from observational data. Catheterization and Cardiovascular Interventions, 2016, 88, 697-707.	0.7	4
323	Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. Current Atherosclerosis Reports, 2016, 18, 5.	2.0	4
324	Practice Variation in Triple Therapy for Patients With Both Atrial Fibrillation and Coronary Artery Disease. JACC: Clinical Electrophysiology, 2016, 2, 36-43.	1.3	4

#	Article	IF	Citations
325	The Effect of Survivor BiasÂon Observational Analyses of Staged PCI in STEMI Patients. JACC: Cardiovascular Interventions, 2017, 10, 629-630.	1.1	4
326	Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. Expert Review of Cardiovascular Therapy, 2017, 15, 681-693.	0.6	4
327	Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review. Future Cardiology, 2018, 14, 251-267.	0.5	4
328	Challenges of Assessing Therapeutic or Diagnostic Outcomes with Observational Data. American Journal of Medicine, 2018, 131, 206-210.	0.6	4
329	Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survivalâ€"The Key Is Immortality. JAMA Cardiology, 2018, 3, 443.	3.0	4
330	The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. Canadian Journal of Cardiology, 2018, 34, 1648-1654.	0.8	4
331	In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure. American Journal of Cardiology, 2018, 122, 381-387.	0.7	4
332	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	4
333	Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention. International Journal of Cardiology, 2020, 299, 75-80.	0.8	4
334	Thirty-Day Spending and Outcomes for an Episode of Pneumonia Care Among Medicare Beneficiaries. Chest, 2020, 157, 1241-1249.	0.4	4
335	Misclassification of Hospital Performance Under the Hospital Readmissions Reduction Program. JAMA Cardiology, 2021, 6, 332.	3.0	4
336	Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segmentâ€"Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circulation: Cardiovascular Interventions, 2021, 14, e010323.	1.4	4
337	Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. European Heart Journal, 2015, 36, 1216-1218.	1.0	3
338	Reply. Journal of the American College of Cardiology, 2015, 66, 2056.	1.2	3
339	Letter by Wasfy et al Regarding Article, â€œFacility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Programâ€• Circulation. 2016, 133, e376.	1.6	3
340	Management of Complications. Interventional Cardiology Clinics, 2016, 5, 201-209.	0.2	3
341	Landscape of Cardiovascular Device Registries in the United States. Journal of the American Heart Association, 2019, 8, e012756.	1.6	3
342	Treating Symptomatic Aortic Stenosis With Transcatheter Aortic Valve Replacement: Is There Time to Wait?. Journal of the American Heart Association, 2019, 8, e011527.	1.6	3

#	Article	IF	Citations
343	Association of symptom status, myocardial viability, and clinical/anatomic risk on longâ€term outcomes after chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 996-1008.	0.7	3
344	Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice. JACC: Cardiovascular Interventions, 2021, 14, 2112-2123.	1.1	3
345	Accuracy of Administrative Claims Codes for Identifying Devices Used in Endovascular Femoropopliteal Artery Revascularisation: A Retrospective Observational Study at Two Tertiary Centres in the United States. European Journal of Vascular and Endovascular Surgery, 2022, 63, 769-770.	0.8	3
346	Patent Foramen Ovale Closureâ€"Harnessing Clinical Trial Evidence to Inform Individualized Treatment Decisions. JAMA - Journal of the American Medical Association, 2021, 326, 2265.	3.8	3
347	Defining Unavoidable Delays in Primary Percutaneous Coronary Intervention: Discordance Among Patients Excluded From National Cardiovascular Quality Registries. Journal of the American Heart Association, 2014, 3, e000944.	1.6	2
348	Response to Letter Regarding Article, â€œSurgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Interventionâ€• Circulation, 2015, 132, e156.	1.6	2
349	Assessing the optimal strategy for dual antiplatelet therapy. Expert Review of Cardiovascular Therapy, 2015, 13, 1067-1069.	0.6	2
350	Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine. Journal of Thoracic Disease, 2016, 8, E1226-E1229.	0.6	2
351	Should We Care About Short-Term Readmissions After Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	2
352	Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Progress in Cardiovascular Diseases, 2018, 60, 491-499.	1.6	2
353	Re: Multivessel Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology, 2018, 29, e59-e60.	1.2	2
354	Exposure Misclassification in Observational Studies. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004939.	0.9	2
355	Suitability of elderly adult hospital readmission rates for profiling readmissions in younger adult and pediatric populations. Health Services Research, 2020, 55, 277-287.	1.0	2
356	Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006887.	0.9	2
357	Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial. American Heart Journal, 2022, 243, 77-86.	1.2	2
358	Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheterization and Cardiovascular Interventions, 2022, 99, 263-270.	0.7	2
359	The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. Journal of Invasive Cardiology, 2017, 29, 264-270.	0.4	2
360	â€˜State of the Artâ€™ PCI: bridging the implementation gap. European Heart Journal, 2022, 43, 1317-1319.	1.0	2

#	Article	IF	Citations
361	Episodic ventricular pacing with intact atrioventricular nodal function in a DDDR device: What is the rhythm and how can it be prevented?. Heart Rhythm, 2008, 5, 897-898.	0.3	1
362	Strategies for Postmarketing Surveillance of Drugs and Devices in Patients with ESRD Undergoing Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2213-2220.	2.2	1
363	Evaluation and Management of ST-elevation Myocardial Infarction and Shock. European Cardiology Review, 2014, 9, 88.	0.7	1
364	Cardiovascular Event Risk After Noncardiac Surgery. JAMA - Journal of the American Medical Association, 2014, 311, 525.	3.8	1
365	Impact of Academic Year Timing on Percutaneous Coronary Intervention Outcomes at Training Institutions. Journal of the American College of Cardiology, 2014, 63, 1025-1026.	1.2	1
366	Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study). American Journal of Cardiology, 2014, 113, 1146-1152.	0.7	1
367	Reply. Journal of the American College of Cardiology, 2015, 66, 1204-1205.	1.2	1
368	Mortality risk with dual antiplatelet therapy?. Lancet, The, 2015, 386, 1533-1534.	6.3	1
369	Letter by Secemsky et al Regarding Article, â€œRelationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271â€‰845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Scoreâ€“Corrected Analysis From the British Cardiovascular Intervention Societyâ€. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	1
370	Editorial Commentary: Hard questions for mobile technology in cardiology. Trends in Cardiovascular Medicine, 2016, 26, 387-388.	2.3	1
371	IMPACT OF CORONARY ANATOMICAL COMPLEXITY ON THE EFFECT OF EXTENDED DURATION DUAL ANTIPLATELET THERAPY: AN ANALYSIS FROM THE DUAL ANTIPLATELET THERAPY STUDY. Journal of the American College of Cardiology, 2017, 69, 1011.	1.2	1
372	EMPLOYING THE MULTIDISCIPLINARY HEART TEAM APPROACH FOR COMPLEX CORONARY ARTERY DISEASE: A SINGLE CENTER EXPERIENCE. Journal of the American College of Cardiology, 2017, 69, 2544.	1.2	1
373	Reply. JACC: Cardiovascular Interventions, 2017, 10, 1468-1469.	1.1	1
374	Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction. Coronary Artery Disease, 2017, 28, 634-635.	0.3	1
375	State Variation in the Use of Non-Acute Coronary Angiograms and Coronary Revascularization Procedures. JACC: Cardiovascular Interventions, 2018, 11, 912-913.	1.1	1
376	GEOGRAPHIC VARIATION AND TRENDS IN OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN UNITED STATES. Journal of the American College of Cardiology, 2019, 73, 1092.	1.2	1
377	INCIDENT HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE NCDR REGISTRIES LINKED WITH ALL-PAYER CLAIMS DATABASE. Journal of the American College of Cardiology, 2019, 73, 103.	1.2	1
378	Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice. JAMA Cardiology, 2019, 4, 564.	3.0	1

#	Article	IF	Citations
379	Hospital-Specific Mortality for Acute Myocardial Infarction Versus Emergency Percutaneous Coronary Intervention in New York State. JACC: Cardiovascular Interventions, 2019, 12, 898-899.	1.1	1
380	PROCEDURAL OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTIONS FOR CHRONIC TOTAL OCCLUSIONS IN PATIENTS WITH LOW LEFT VENTRICULAR EJECTION FRACTION: INSIGHTS FROM THE PROGRESS CTO REGISTRY. Journal of the American College of Cardiology, 2019, 73, 1279.	1.2	1
381	SCOT-HEART: Does it live up to the PROMISE?. Journal of Cardiovascular Computed Tomography, 2019, 13, 48-50.	0.7	1
382	CMS Quality Measure Developmentâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1214.	3.8	1
383	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€• Circulation, 2020, 142, e212-e213.	1.6	1
384	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. Revista Espanola De Cardiologia (English Ed), 2020, 74, 1023-1031.	0.4	1
385	Database Inaccuracies and Disparities in Care Among Homeless Adults Hospitalized for Cardiovascular Conditionsâ€"Reply. JAMA Internal Medicine, 2020, 180, 614.	2.6	1
386	Prognosis of Claimsâ€•Versus Trialâ€Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal of the American Heart Association, 2021, 10, e018744.	1.6	1
387	Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. Journal of Cardiovascular Electrophysiology, 2021, 32, 1529-1537.	0.8	1
388	Comparing Baseline Data From Registries With Trials. JACC: Cardiovascular Interventions, 2021, 14, 1386-1388.	1.1	1
389	Association Between Diagnosis Code Expansion and Changes in 30â€Day Riskâ€Adjusted Outcomes for Cardiovascular Diseases. Journal of the American Heart Association, 2021, 10, e020668.	1.6	1
390	Expansion of insurance under the affordable care act and invasive management of acute myocardial infarction. Cardiovascular Revascularization Medicine, 2021, , .	0.3	1
391	Hospital-Level Percutaneous Coronary Intervention Performance With SimulatedÂRisk Avoidance. Journal of the American College of Cardiology, 2021, 78, 2213-2217.	1.2	1
392	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. Cardiovascular Revascularization Medicine, 2022, , .	0.3	1
393	DES and DAPT in Evolution. JACC: Cardiovascular Interventions, 2022, 15, 278-281.	1.1	1
394	Association of Cholesterol Efflux Capacity with Adverse Cardiovascular Outcomes: A Meta-Analysisâ€. Journal of Clinical Lipidology, 2022, 16, e1-e2.	0.6	1
395	PO-656-04 SAFETY AND EFFECTIVENESS OF SAME DAY DISCHARGE AFTER LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX. Heart Rhythm, 2022, 19, S268.	0.3	1
396	Fatal hyperphosphatemia after oral phospho-soda bowel preparation for colonoscopy: a case report and review of the literature. American Journal of Gastroenterology, 2000, 95, 2613-2613.	0.2	0

#	Article	IF	Citations
397	CORONARY PLAQUE CHARACTERISTICS IN PATIENTS WITH METABOLIC SYNDROME: COMPARISON TO THOSE WITH DIABETES AND WITH NORMAL GLYCEMIA: AN OPTICAL COHERENCE TOMOGRAPHY STUDY. Journal of the American College of Cardiology, 2012, 59, E1433.	1.2	0
398	TCT-742 Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From PROTECT. Journal of the American College of Cardiology, 2012, 60, B216-B217.	1.2	0
399	Another View of Personalized Medicine: Optimizing Stent Selection on the Basis of Predicted Benefit in Percutaneous Coronary Intervention. Trends in Cardiovascular Medicine, 2012, 22, 23-28.	2.3	0
400	Caesarian Dissection. Circulation, 2013, 127, 1530-1535.	1.6	0
401	The Challenges of Success. Circulation, 2014, 130, 1343-1345.	1.6	0
402	Dual antiplatelet therapy duration and mortality â€“ Authors' reply. Lancet, The, 2015, 385, 2149-2150.	6.3	0
403	Coronary CT angiography for myocardial infarction. Coronary Artery Disease, 2016, 27, 72-73.	0.3	0
404	TCT-284 Interrelationship between depression, angina, and dyspnea before and after CTO PCI in the OPEN CTO Registry. Journal of the American College of Cardiology, 2016, 68, B116-B117.	1.2	0
405	TEMPORAL TRENDS AND OPERATOR VARIATION IN ANTICOAGULANT USE DURING PERCUTANEOUS CORONARY INTERVENTION FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN THE UNITED STATES. Journal of the American College of Cardiology, 2016, 67, 465.	1.2	0
406	IMPLICATIONS OF THE DUAL-ANTIPLATELET THERAPY (DAPT) TRIAL IN THE REAL WORLD: INSIGHTS FROM THE NCDR RESEARCH TO PRACTICE INITIATIVE. Journal of the American College of Cardiology, 2017, 69, 22.	1.2	0
407	A COST-EFFECTIVE ANALYSIS OF SHORT DURATION DUAL ANTI-PLATELET THERAPY (DAPT) WITH A BIOABSORBABLE POLYMER STENT PLATFORM VERSUS LONGER DURATION DAPT WITH A DURABLE POLYMER DRUG-ELUTING STENT IN A PATIENT POPULATION UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2017, 69, 1253.	1.2	0
408	THE IMPACT OF EPICARDIAL COLLATERAL USE ON THE OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM A CONTEMPORARY MULTICENTER REGISTRY. Journal of the American College of Cardiology, 2017, 69, 1319.	1.2	0
409	APPLICATION AND OUTCOMES OF THE HYBRID APPROACH TO CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: AN UPDATE FROM A CONTEMPORARY MULTICENTER U.S. REGISTRY. Journal of the American College of Cardiology, 2017, 69, 1323.	1.2	0
410	NATIONWIDE READMISSIONS FOLLOWING LOWER EXTREMITY ARTERIAL PROCEDURES. Journal of the American College of Cardiology, 2017, 69, 2013.	1.2	0
411	TCT-21 Prevalence, Presentation and Treatment of â€˜Balloon Undilatableâ€™ Chronic Total Occlusions: Multicenter US Experience. Journal of the American College of Cardiology, 2017, 70, B9-B10.	1.2	0
412	Risk score identifies patients who will benefit from prolonged dual antiplatelet therapy. BMJ Evidence-Based Medicine, 2018, 23, 73-74.	1.7	0
413	Understanding How to Improve Quality and Value for Patients With Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 102.	3.0	0
414	TCT-138 Comparison Between Traditional and Guide Catheter Extension Reverse CART: Insights From the PROGRESS-CTO Registry. Journal of the American College of Cardiology, 2018, 72, B59-B60.	1.2	0

#	Article	IF	Citations
415	TCT-78 Impact of Collateral Channel Type on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2018, 72, B34-B35.	1.2	0
416	Inadequate Surrogates for Imperfect Quality Measures. Circulation: Cardiovascular Interventions, 2018, 11, e007216.	1.4	0
417	Putting Theory to the Test. Circulation: Cardiovascular Interventions, 2019, 12, e007953.	1.4	0
418	Myocardial Perfusion After Coronary Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e008568.	1.4	0
419	Reply. Journal of the American College of Cardiology, 2019, 74, 2219.	1.2	0
420	Paving a Road to PCI Quality With GoodÂIntentions and Rigorous Statistics. JACC: Cardiovascular Interventions, 2019, 12, 1976-1978.	1.1	0
421	Reply. JACC: Cardiovascular Interventions, 2019, 12, 108-109.	1.1	0
422	FINANCIAL AND ADMINISTRATIVE BURDEN OF PUBLIC REPORTING OF PERCUTANEOUS CORONARY INTERVENTION OUTCOMES IN MASSACHUSETTS. Journal of the American College of Cardiology, 2019, 73, 1050.	1.2	0
423	IMPACT OF DISTAL VESSEL QUALITY ON ACUTE PROCEDURAL OUTCOMES IN CTO PCI: INSIGHT FROM THE PROGRESS CTO REGISTRY. Journal of the American College of Cardiology, 2019, 73, 1278.	1.2	0
424	CONTEMPORARY OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTIONS: UPDATE FROM THE PROGRESS CTO (PROSPECTIVE GLOBAL REGISTRY FOR THE STUDY OF CHRONIC TOTAL) Tj ET Q q 0 0 0 rg BT /Overlo	1.2	0
425	Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coronary Artery Disease, 2019, 30, 177-182.	0.3	0
426	Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. Coronary Artery Disease, 2020, 31, 230-236.	0.3	0
427	Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. Journal of Endovascular Therapy, 2021, 28, 246-254.	0.8	0
428	Clinical risk scores: a tool to understand bleeding and thrombotic risk. , 2021, , 145-166.		0
429	Adjusting for population differences using machine learning methods. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 750-769.	0.5	0
430	Relation of the Number of Cardiovascular Conditions and Short-term Symptom Improvement After Percutaneous Coronary Intervention for Stable Angina Pectoris. American Journal of Cardiology, 2021, 155, 1-8.	0.7	0
431	National trends in utilization of thrombolytic therapy for acute pulmonary embolism. Vascular Medicine, 2021, , 1358863X2110485.	0.8	0
432	Inadvertent Femoral Endarterectomy: A Complication from a Suture-based Vascular Closure Device. Journal of Vascular Access, 2011, 12, 71-72.	0.5	0

#	Article	IF	Citations
433	Abstract 161: National Trends in Use of Radial Access for Percutaneous Coronary Intervention in China: 2001-2011. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, .	0.9	0
434	A Need For Long-Term Results of LMCA-CTO-PCI. Journal of Invasive Cardiology, 2019, 31, E342.	0.4	0